Exchange: NASDAQ·Updated 03:44 PM EDT
News
all
press releases
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposium 2 at the International Association for the Study of Lung Cancer's...
Business Wire
More News
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the...
Business Wire
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell Technology Inc (NASDAQ: MRVL) surged in pre-market trading after securing a spot in the S&P 500...
Benzinga
Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks
Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks $NTHI, $ORKA, $ABVX, $CGEM, $SYRE, $APGE
24-7 Market News
The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...
Business Wire
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 8,000 shares of the business's stock in a transaction that occurred on Tuesday, May 5th. The shares were...
MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5.6% - Time to Sell?
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5.6% - Here's What Happened...
MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a h...
MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading 8.5% Higher - Here's Why
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 8.5% - Time to Buy...
MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Receives "Buy" Rating from BTIG Research
BTIG Research reiterated a "buy" rating and issued a $38.00 price objective on shares of Cullinan Therapeutics in a report on Monday...
MarketBeat

Advertisement|Remove ads.